03.06.15
Isis Pharmaceuticals, Inc. has earned a $9 million milestone payment from Biogen Idec related to advancing the Phase III study evaluating ISIS-SMNRx in infants with spinal muscular atrophy (SMA).
The ENDEAR study will evaluate the efficacy and safety of a 12 mg dose of ISIS-SMNRx with a primary endpoint of survival or time to permanent ventilation in approximately 110 infants diagnosed with SMA.
The ENDEAR study will evaluate the efficacy and safety of a 12 mg dose of ISIS-SMNRx with a primary endpoint of survival or time to permanent ventilation in approximately 110 infants diagnosed with SMA.